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Physical and Functional Interaction
between GATA-3 and Smad3 Allows
TGF- Regulation of GATA Target Genes
the molecular level remains a major challenge. Signal
integration may take place at target promoters through
the modular arrangement of DNA binding sites for differ-
ent transcription factors. These may include signal-acti-
vated factors, regulated by extracellular signals, and
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2 Division of Cellular Biochemistry bility for integration of genetic and epigenetic inputs
involves the direct recruitment of signal-activated fac-The Netherlands Cancer Institute
Amsterdam tors to target promoters by tissue-restricted factors.
GATA-3 is a member of the GATA family of zinc finger-The Netherlands
containing transcription factors, best known for their
important roles in the control of cell fate decisions in
different hematopoietic cell lineages [1–3]. Targeted dis-Summary
ruption of the GATA-3 gene in mice results in embryonic
death on day 12, with failure of fetal liver hematopoiesisBackground: Members of the GATA family of zinc finger
and defects in the central and peripheral nervous sys-transcription factors are genetically controlled “master”
tems [4, 5]. In mouse chimeras, GATA-3/ ES cells failregulators of development in the hematopoietic and ner-
to give rise to thymocytes or mature peripheral T cells,vous systems. Whether GATA factors also serve to inte-
indicating that GATA-3 is an essential and specific regu-grate epigenetic signals on target promoters is, however,
lator of early thymocyte development [6]. In addition tounknown. The transforming growth factor- (TGF-) su-
its role in T cell development, GATA-3 is an indispens-perfamily is a large group of phylogenetically conserved
able differentiation factor for a subtype of T helper cellssecreted factors controlling cell proliferation, differenti-
(Th2), characterized by their ability to produce a specification, migration, and survival in multiple tissues.
set of cytokines, including IL-4, IL-5, and IL-10, and to
promote humoral immunity. GATA-3 DNA binding sitesResults: GATA-3, a key regulator of T helper cell devel-
have been found in the IL-4 and IL-5 gene promoters,opment, was found to directly interact with Smad3, an
and GATA-3 is necessary for the expression of all Th2intracellular signal transducer of TGF-. Complex forma-
cytokine genes [7, 8]. Cytokine gene expression cantion required a central region in GATA-3 and the N-ter-
be regulated by a vast number of extracellular signals,minal domain of Smad3. GATA-3 mediated recruitment
including antigen stimulation, membrane-bound cofac-of Smad3 to GATA binding sites independently of Smad3
tors, soluble hormones, and other cytokines and growthbinding to DNA, and the two factors cooperated syner-
factors. It is, however, unknown whether GATA proteinsgistically to regulate transcription from the IL-5 promoter
are able to directly integrate signals from extracellularin a TGF--dependent manner. Treatment of T helper
stimuli at cytokine gene promoters.cells with TGF- promoted the formation of an endoge-
Members of the TGF- superfamily are pleiotropic-nous Smad3/GATA-3 nuclear complex and stimulated
secreted polypeptides regulating proliferation, cell fate,production of the Th2 cytokine IL-10 in a Smad3- and
differentiation, migration, adhesion, and apoptosis inGATA-3-dependent manner.
numerous cell types. The TGF- is one of the largest
families of growth factors known and includes TGF-s,Conclusions: Although Smad proteins are known to in-
bone-morphogenetic proteins (BMPs), activins, nodals,teract with a number of general transcription factors,
and growth and differentiation factors (GDFs), alto-these are insufficient to explain the tissue-specific biol-
gether comprising more than 30 different proteins.ogy of TGF- proteins. Through its interaction with
TGF- family members are expressed in complexSmad3, GATA-3 is able to integrate a genetic program
spatio-temporal patterns and play important roles inof cell differentiation with an extracellular signal, provid-
development, homeostasis, and repair in practically alling a molecular framework for the effects of TGF- on
tissues, from flies to humans. In comparison to this widethe development and function of specific subsets of
functional diversity, the signal transduction mechanismimmune cells and possibly other cell types.
of TGF- proteins appears deceptively simple. Two re-
ceptor serine-threonine kinases cooperate to bind li-
Introduction gand, one of the kinases phosphorylates the other, and
the latter phosphorylates specific members of a family
In many cell lineages, cell fate decisions and phenotypic of signal transducers (i.e., Smad proteins) that move
differentiation are determined by intrinsic transcriptional into the nucleus, where they participate in DNA binding
programs coordinated by extracellular signals provided complexes [9–11]. Remarkably, only a few Smads, i.e.,
by local organizer centers. The understanding of how Smads 2 and 3 for TGF-s and activins/nodals and
genetic and epigenetic mechanisms are integrated at Smads 1, 5, and 8 for BMPs and certain GDFs, are in
charge of mediating the activities of all TGF- proteins
known. Although some Smads (Smad3 and Smad4, a3 Correspondence: carlos.ibanez@neuro.ki.se
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common partner of all receptor-regulated Smads) have
intrinsic DNA binding activities, the large diversity of
genes regulated by TGF- proteins can not be solely
explained bases on the presence of Smad binding ele-
ments in the promoters of target genes. Smads have
been found to require other sequence-specific factors
to bind efficiently to the promoters of certain responsive
genes [9–11]. Although a number of general transcription
factors, coactivators, and corepressors have been
found to associate with Smad proteins, these are ex-
pressed in most cell types and are therefore insufficient
to explain the manifold tissue-specific target gene selec-
tion observed in response to TGF- family proteins.
In the immune system, TGF- proteins have complex
and cell context-dependent effects on cell proliferation,
survival, and differentiation [12, 13]. In particular, these
proteins play a crucial instructive role in the specification
of distinct profiles of cytokine production by effector
cells. The importance of Smad proteins in the regulation
of immune function by TGF- is underscored by the
profound deficits in T cell activation, mucosal immunity,
and cytokine production observed in mice lacking
Smad3 [14, 15]. This Smad protein is particularly abun-
dant in cells of immune origin and is therefore likely to
be one of the main mediators of TGF- responses in
these cells. The specific transcription factors that part-
ner with Smad3 to allow regulation of gene expression
by TGF- in immune cells are, however, unknown.
In the work reported here, we have investigated the
possibility that GATA-3 integrates TGF- signaling at
target promoters via interaction with Smad proteins. Our
results indicate that GATA-3 interacts physically and
functionally with Smad3, allowing TGF- regulation of
GATA-3 target genes.
Results
Synergistic Cooperation of GATA-3 and Smad3
Figure 1. Synergistic Interaction between Smad3 and GATA-3 in
in the Activation of the IL-5 Promoterthe Regulation of the IL-5 Promoter
Prompted by parallels between the activities of GATA-3
(A) Luciferase activity in lysates of HepG2 cells transfected with a
and some of the effects of TGF- proteins, we decided1.2-kb IL-5 promoter construct in the presence or absence of
to investigate the possibility that GATA-3 may cooperateGATA-3 and PMA/ionomycin (PI) treatment as indicated. Cells were
left untreated (open bars) or were treated overnight with 10 ng/ with Smads to mediate TGF- responses in GATA target
ml TGF- (solid bars) or BMP4 (gray bars). Normalized results are genes.
expressed relative to control as the average SD of triplicate deter- We first investigated whether GATA-3-dependent
minations. gene transcription can be regulated by TGF- signaling.
(B) Luciferase activity in lysates of HepG2 cells transfected with the
To this purpose, we utilized a DNA fragment containingIL-5 promoter construct in the absence (open bars) or presence
1.2 kb from the IL-5 promoter coupled to a luciferase(solid bars) of GATA-3 and increasing amounts of TGF- (overnight
treatment). Cells were also treated with PMA/ionomycin. Normalized reporter gene. This construct contains GATA-3 DNA
results are expressed relative to control as the average  SD of binding sites and can be transactivated by GATA-3 in
triplicate determinations. response to T cell activation or in cells stimulated with
(C) Role of individual Smad proteins in the regulation of IL-5 pro- PMA and ionomycin (used as a surrogate of antigen
moter activity by TGF- ligands. Different amounts of Smad expres-
receptor stimulation, also see the Experimental Proce-sion plasmids, as indicated, were transfected along with the IL-5
reporter construct in HepG2 cells in the presence or absence of
GATA-3 and TGF- ligands (TGF-1 for Smads 2, 3, and 4 and
BMP-4 for Smad1) at 10 ng/ml. Cells were also treated with PMA/
ionomycin. Normalized results are expressed relative to control as expressed relative to control as the average SD of triplicate deter-
the average  SD of triplicate determinations. minations.
(D) Smad3 binding to DNA is not required for synergistic cooperation (E) Luciferase activity in lysates of HepG2 cells transfected with a
with GATA-3. Wild-type or K81R mutant Smad3 were transfected synthetic multimerized GATA reporter construct in the presence or
in HepG2 cells along with the IL-5 reporter construct in the presence absence of Smad3, GATA-3, and TGF- (10 ng/ml). In this case, the
or absence of GATA-3 and TGF- (10 ng/ml). Cells were also treated cells were not treated with PMA/ionomycin. Normalized results are
with PMA/ionomycin. The K81R Smad3 mutant is not able to bind expressed relative to control as the average SD of triplicate deter-
DNA but can still cooperate with GATA-3. Normalized results are minations.
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dures) [16]. Neither TGF- nor BMP4 were able to stimu-
late transcription from the IL-5 promoter in naı¨ve HepG2
cells, an epithelial cell line that is highly responsive to
several members of the TGF- superfamily (Figure 1A).
Treatment with PMA and ionomycin or transfection of
GATA-3 had no effect on the IL-5 promoter on their
own, nor did they allow responsiveness to TGF- ligands
(Figure 1A). However, GATA-3 was able to stimulate
transcription from the IL-5 promoter in HepG2 cells
treated with PMA and ionomycin, in agreement with
previous reports (Figure 1A). Under these conditions,
TGF-, but not BMP4, augmented the activity of this
promoter (Figure 1A). The effects of TGF- were dose
dependent, with a plateau between 5 and 10 ng/ml (Fig-
ure 1B). Together, these data indicated that the regula-
Figure 2. Mutation of the GATA-3 Binding Site in the IL-5 Promotertory effects of TGF- on the IL-5 promoter were depen-
Abolishes TGF- Responsiveness
dent on the presence of GATA-3.
Luciferase activity in lysates of Jurkat cells transfected with a wild-We evaluated the role of individual Smad proteins on
type (IL5-luc) IL-5 promoter construct or a mutant construct lacking
the activation of the IL-5 promoter by GATA-3 and the GATA-3 binding element (IL5mut-luc). Promoter activity was
TGF-. In the absence of GATA-3, overexpression of tested in the presence or absence of exogenous GATA-3 and Smad3
(the latter at 150 ng plasmid DNA). Cells were also treated withSmad proteins had no effect on the activity of the IL-5
PMA/ionomycin. TGF- signaling was activated in Jurkat cells bypromoter in HepG2 cells, even after stimulation with
the introduction of a constitutively activated TGF- receptor (CA-TGF- ligands (Figure 1B). However, transfection of
ALK5, solid bars). Normalized results are expressed relative to con-Smad3 increased the activity of the IL-5 promoter in a
trol as the average  SD of triplicate determinations.
dose-dependent manner in cells that also received
GATA-3 (Figure 1C, solid bars). Smad2 had only a mod-
est effect, while Smad1 and Smad4 were inactive (Figure signaling by testing the activity of the IL-5 promoter
1B). In the presence of GATA-3, small amounts of Smad3 construct in Jurkat cells, a lymphoid T cell line express-
dramatically increased the responsiveness of the IL-5 ing moderate levels of endogenous GATA-3. Due to the
promoter to TGF- (Figure 1C, stippled bars), indicating low levels of TGF- receptors expressed in these cells,
a synergistic cooperation of these two factors to regu- a constitutively active form of the type I TGF- receptor
late ligand-dependent gene transcription. Smad3 con- TRI (CA-ALK5) was used to activate the TGF--signal-
tains DNA binding activity with low affinity toward ing pathway. CA-ALK5 was able to increase IL-5 pro-
5-TCTGAGAC-3, termed the Smad binding element moter activity in Jurkat cells that also received moderate
(SBE) [17, 18]. The SBE is absent from the 1.2-kb IL-5 levels of Smad3 (Figure 2, left side). Exogenous GATA-3
promoter fragment, suggesting that Smad3 binding to elevated the activity of the IL-5 promoter, and this could
DNA is not required for transactivation of this promoter be further increased by CA-ALK5 (Figure 2, left side).
in the presence of GATA-3. To examine this possibility Thus, GATA-3 and Smad3 cooperated synergistically to
directly, we made use of a point mutant in the conserved transactivate this promoter in Jurkat cells and to confer
 hairpin of the MAD homology 1 (MH1) domain of responsiveness to the constitutively activated TGF-
Smad3, which is the DNA binding domain of Smads [19]. receptor (Figure 2, left side). These results indicated
As predicted from the crystal structure, mutation of Lys- that, in the presence of GATA-3, activation of the TGF-
81 into Arg (K81R) completely abolishes binding of
-signaling pathway can also elevate the activity of the
Smad3 to the SBE [20]. The K81R Smad3 mutant still 1.2-kb IL-5 promoter fragment in cells of lymphoid origin.
retained the ability to potentiate transcription from the Finally, to further test the role of GATA-3 in conferring
IL-5 promoter in the presence of GATA-3 and TGF- responsiveness to TGF- signaling to the IL-5 promoter,
(Figure 1D), indicating that Smad3 may not need to bind we examined the activity of a mutated IL-5 promoter
DNA directly in order to cooperate with GATA-3 to regu- construct in which the GATA binding element had been
late gene transcription. The transcriptional activity of a replaced by an irrelevant sequence. As predicted by our
construct containing a concatemerized GATA binding previous results, this promoter construct was no longer
site in front of a minimal promoter was also stimulated responsive to activation of the TGF--signaling pathway
by GATA-3 in HepG2 cells (Figure 1E). GATA-3 allowed (Figure 2, right side).
TGF- to upregulate the activity of this synthetic pro-
moter in cells that also received additional Smad3 (Fig-
TGF--Dependent Formation of Transcriptionure 1E). Importantly, Smad3 was unable to bind to the
Factor Complexes on GATA-Specific DNAGATA oligonucleotide used to generate this promoter
Binding Sites(see below). TGF- had no effect in the absence of
The results presented above suggested that GATA-3GATA-3 (Figure 1E), even in the presence of additional
may be able to recruit Smad3 to DNA binding sitesSmad3, suggesting that GATA-3 may have the ability to
specific for GATA proteins, thereby conferring TGF-confer TGF- responsiveness to a variety of promoters
responsiveness to target promoters. We therefore inves-containing GATA binding sites.
tigated protein/DNA interactions using an oligonucleo-We also examined the influence of cellular context
on the responsiveness of the IL-5 promoter to TGF- tide probe containing a consensus binding site for GATA
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Figure 3. Interaction of the Smad3/GATA-3
Complex with GATA DNA Binding Sites and
Regulation by TGF-
(A) Specificity of the GATA oligonucleotide
probe. Nuclear extracts of COS cells trans-
fected with HA-tagged GATA-3 or myc-
Smad3 constructs as indicated were used in
electrophoretic mobility shift assays with a
DNA probe based on a consensus binding
site for GATA family factors. Excess unla-
beled oligonucleotide was used as specificity
control (competitor). Supershift by an anti-
HA antibody demonstrated the presence of
GATA-3 in the complex (open arrow). Smad3
was unable to shift the GATA oligonucleotide.
Specific protein/DNA complexes are indi-
cated by arrows.
(B) Binding of endogenous GATA-3 from HT-2 cells to GATA DNA binding sites. Nuclear extracts of HT-2 cells were used in electrophoretic
mobility shift assays with a GATA DNA probe. No PMA/ionomycin treatment was done for this experiment. A 100-fold excess of unlabeled
oligonucleotide was used as specificity control (competitor). Supershift by an anti-GATA-3 antibody demonstrated the presence of GATA-3
in the complex (open arrow).
(C) Electrophoretic mobility shift assays with nuclear extracts from HT-2 cells expressing endogenous GATA-3. Extracts from control cells or
cells transfected with a Smad3 expression construct were used as indicated. Prior to the preparation of the extracts, some cells were treated
with 10 ng/ml TGF- for 50 min as indicated. No PMA/ionomycin treatment was done for this experiment. GATA-3/DNA complexes are
indicated with a solid arrow. The open arrow indicates supershifted complexes.
factors in electrophoretic mobility shift assays. Hemag- 35S-labeled GATA-3 (Figure 4A). GST-Smad3, but not
GST alone, was also able to pull down endogenousglutinin (HA)-tagged GATA-3 produced in nuclear ex-
tracts of transiently transfected COS cells was able to GATA-3 from lysates of Jurkat cells (Figure 4B). The
interaction between Smad3 and GATA-3 was then stud-specifically bind to the radiolabeled GATA oligonucleo-
tide probe (Figure 3A). This complex could be displaced ied in vivo in mammalian cells. A myc-tagged Smad3
and a HA-tagged GATA-3 were transiently transfectedwith cold competitor oligonucleotide and supershifted
with anti-HA antibodies (Figure 3A), demonstrating its into COS cells. Overexpression of Smad3 in COS cells
results in ligand-independent accumulation of this pro-specificity. Smad3 did not bind to the GATA oligonucleo-
tide probe (Figure 3A). We then examined nuclear ex- tein in the nucleus (unpublished data). Immunoprecipita-
tion with anti-HA antibodies allowed the recovery oftracts from the TGF--responsive T helper cell line HT-2.
An endogenous GATA DNA binding activity similar to myc-tagged Smad3 only from nuclear extracts of cells
that received the HA-GATA-3 construct (Figure 4C),that observed in transfected COS cells was detected in
these cells (Figure 3B). This could be displaced by cold demonstrating the formation of a complex between
Smad3 and GATA-3 in vivo. In agreement with the speci-competitor oligonucleotide and supershifted with anti-
GATA-3 antibodies (Figure 3B). Overexpression of Smad3 ficity observed in the transactivation of the IL-5 promoter
in HepG2 cells, GATA-3 associated preferentially within HT-2 cells resulted in the appearance of small
amounts of a higher-molecular weight complex (open Smad3 over other Smad proteins after overexpression
in COS cells (Figure 4C). Only very low levels of Smad1arrow in Figure 3C, lane 4). Formation of this complex
was greatly stimulated following a short exposure (15 could be recovered following GATA-3 immunoprecipita-
tion, while Smad2 and Smad4 were undetectable inmin) to TGF- (Figure 3C, lane 3), indicating that TGF-
can induce the formation of high-order protein/DNA GATA-3 immunoprecipitates (Figure 4C). Under the
same conditions, we could neither recover Smad4 incomplexes on GATA-specific DNA sequences in im-
mune cells. The fact that this complex could only be GATA-3 immunoprecipitates prepared from cells that
also overexpressed Smad3 (Figure 4C, right panel), sug-observed in cells after transfection of Smad3 suggests
that it may contain this Smad protein in complex with gesting that Smad4 does not form part of the Smad3/
GATA-3 complex. In agreement with this observation,GATA-3 bound to the DNA oligonucleotide probe. The
lack of effect of the TGF- treatment in the absence of overexpression of Smad4 did not affect the ability of
CA-ALK5 and Smad3 to transactivate the IL-5 promoteroverexpressed Smad3 may be due to insufficient endog-
enous levels of this Smad protein for detection in the in Jurkat cells (Figure 4D), although it had dramatic ef-
fects on the activity of a synthetic promoter carryingshift assay.
multimerized SBE sites (Figure 4D).
To identify which of the domains of Smad3 mediated
The Interaction between GATA-3 its interaction with GATA-3, we tested the ability of dif-
and Smad3 Is Direct ferent GST fusion constructs to pull down in vitro-trans-
The results described so far could be best rationalized lated GATA-3. A GST fusion of the C-terminal MH2 do-
by a direct interaction between Smad3 and GATA-3. We main of Smad3, with or without the linker region, was
first investigated this in vitro using a GST-Smad3 fusion unable to interact with GATA-3 (Figure 4A), suggesting
protein produced in bacteria and 35S-labeled GATA-3 that the GATA-3 binding site in Smad3 may be in the
produced by in vitro translation. A GST fusion of full- N-terminal MH1 domain. Indeed, a GST fusion of the
MH1 domain of Smad3 was able to pull down 35S-labeledlength Smad3, but not GST alone, was able to pull down
Functional Interaction between GATA-3 and Smad3
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GATA-3 as efficiently as the full-length protein (Figure
5B). In order to identify the region in GATA-3 involved
in Smad3 binding, we tested several deletion constructs
produced as 35S-labeled in vitro-translated products
(Figure 5A). A GATA-3 construct spanning the first
N-terminal 146 residues did not interact with GST-
Smad3 (Figure 5B). However, extension of this construct
to residue 215 allowed binding to a GST fusion protein
containing the MH1 domain of Smad3 (Figure 5B). This
construct did not interact with GST alone or a GST fusion
of the MH2 domain of Smad3 (Figure 5B). A construct
of the C-terminal region of GATA-3, encompassing the
two zinc finger domains (Zn1 and Zn2 in Figure 5A) was
also pulled down by a GST-Smad3 fusion protein (Figure
5B). Analysis of different GATA-3 deletion constructs in
nuclear lysates of transfected COS cells confirmed the
specific interaction of the first 215 N-terminal residues of
GATA-3 with Smad3 (Figure 5C). The shorter construct
(1–146) did not bind to Smad3 in COS cells (data not
shown). In contrast to the in vitro analysis, however, the
zinc finger region of GATA-3 did not bind to Smad3 in
transfected cells (Figure 5C). This discrepancy could be
due to interference or masking of the GATA-3 zinc finger
region by nuclear DNA or other GATA-interacting pro-
teins or simply that, in vivo, this region is not a bona
fide Smad3 binding site. Together, these data indicate
the presence of a domain in the central portion of the
GATA-3 molecule, between residues 146 and 215, that
interacts with the Smad3 MH1 domain.
TGF- Stimulates the Formation of an Endogenous
Smad3/GATA-3 Complex in the Nucleus
of HT-2 Cells
We investigated Smad3/GATA-3 interactions in a physi-
ological context, taking advantage of the endogenous
expression of these two components in the T helper cell
Figure 4. Physical Interaction of Smad3 with GATA-3 In Vitro and
line HT-2. In untreated cells, immunoprecipitation withIn Vivo
anti-GATA-3 or control antibodies did not bring down
(A) Full-length 35S-labeled GATA-3 produced by in vitro translation
Smad3 in nuclear lysates of HT-2 cells (Figure 6). How-was used in coprecipitation assays together with equal amounts of
ever, after treatment with TGF- for 50 min, endogenousthe indicated GST-Smad fusion proteins. As control, 20% of the
35S-labeled GATA-3 used for the precipitations was run in each gel Smad3 could be detected in GATA-3 immunoprecipi-
(20% input). tates of HT-2 nuclear lysates (Figure 6). Control antibod-
(B) Coprecipitation assay of endogenous GATA-3 from lysates of ies failed to immunoprecipitate Smad3 in any condition
Jurkat cells and GST-Smad fusion proteins. This experiment shows (Figure 6). These results demonstrate a specific and
that GST-Smad3 exogenously added to a lysate of Jurkat cells can
ligand-dependent interaction between endogenousassociate with endogenously expressed GATA-3. The cells had been
GATA-3 and Smad3 in T helper cells.pretreated with PMA/ionomycin, but similar results were obtained
with extracts from untreated cells. Ten percent of the cell lysate
was run as control (10% input). TGF- Regulation of an Endogenous GATA-3 Target
(C) Coimmunoprecipitation of Smad3 and GATA-3 in nuclear lysates
Gene in HT-2 Cells Depends upon the Activitiesof transiently transfected COS fibroblasts. The anti-HA antibody
of Smad3 and GATA-3directed against HA-tagged GATA-3 brings down myc-epitope-
tagged Smad3 only in cells that received the HA-tagged GATA-3 In the last set of experiments, we examined whether
construct (upper left panel). Using a similar coimmunoprecipitation TGF- was able to regulate expression of endogenous
assay, but with different Smad proteins, the upper middle panel GATA-3 target genes in HT-2 cells. Production of several
shows that GATA-3 associates preferentially with Smad3 over other cytokines by Th2 helper cells, including IL-4, IL-5, and
Smads after overexpression in COS cells. The upper right panel
IL-10, is controlled by GATA-3 [7]. HT-2 cells were foundshows that Smad4 does not associate with the Smad3/GATA-3 com-
to secrete IL-10 to the culture medium (Figure 7A). IL-4plex in cells transfected with all three components. A weak Smad4
band of equal intensity can be seen in all three lanes (asterisk). The and IL-5 could not be detected in HT-2 cell supernatants
panels below show Western blots of 20% of the lysates used as input
and reflects the different amounts of Smad and GATA-3 proteins
expressed in the lysates. No PMA/ionomycin treatment was done
for these experiments. or Smad3 as indicated. Cells transfected with the IL-5, but not the
(D) Activity of the IL-5 (left) and CAGA (right) promoters in Jurkat CAGA, reporter construct were also treated with PMA/ionomycin.
cells in the presence (solid bars) or absence (empty bars) of Smad4. Normalized results are expressed relative to control as the aver-
Jurkat cells received exogenous GATA-3 as well as CA-ALK5 and/ age  SD of triplicate determinations.
Current Biology
40
Figure 5. Identification of Protein Domains in Smad3 and GATA-3 Mediating Their Interaction
(A) Domain organization of Smad3 and GATA-3. Deletion constructs of GATA-3 used in in vitro coprecipitation assays are indicated. MH1 and
MH2 denote Mad homology domains 1 and 2, respectively. Zn1 and Zn2 denote the two zinc fingers in GATA-3.
(B) The indicated GATA-3 deletions were 35S-labeled by in vitro translation and used in coprecipitation assays together with equal amounts
of the indicated GST-Smad fusion proteins. As control, 20% of each 35S-labeled GATA-3 protein construct used for the precipitations was
run in each gel (20% input).
(C) Coimmunoprecipitation of Smad3 and GATA-3 deletion constructs in nuclear lysates of transiently transfected COS fibroblasts. See the
legend to Figure 4C for details. No PMA/ionomycin treatment was done for these experiments.
(data not shown). IL-10 production could be further stim- Smad7 protein [22] in HT-2 cells using recombinant ad-
enoviruses. Treatment with TGF- stimulated IL-10 pro-ulated by treatment of HT-2 cells with PMA and iono-
mycin (Figure 7A). In the presence of PMA and iono- duction in uninfected cells and in cells infected with a
control lacZ virus, but failed to increase IL-10 levels inmycin, TGF- was able to stimulate IL-10 production
in supernatants of HT-2 cells maintained in serum-free the supernatant of cells infected with viruses expressing
dominant-negative Smad3 or Smad7 (Figure 7B). Thesemedium for 16 hr (Figure 7A). This effect was observed
data suggest that regulation of IL-10 production byat very low doses of TGF- (i.e., 0.5–50 pg/ml) with a
TGF- in HT-2 cells is dependent on Smad3.peak at 1 pg/ml. At higher doses (i.e.,  500 pg/ml),
We then investigated whether GATA-3 activity wasTGF- had no significant effect on IL-10 production by
required for the regulatory effects of TGF- on IL-10HT-2 cells (Figure 7A).
production in HT-2 cells. To this purpose, we generatedIn order to determine whether the effect of TGF-
stable subclones of HT-2 cells overexpressing a domi-on IL-10 production by HT-2 cells was dependent on
nant-negative GATA-3 isoform (KRR-GATA-3) [23]. Thisactivation of Smad3, we overexpressed a dominant-
GATA-3 molecule carries a triple alanine substitution innegative form of Smad3 (D407E) [21] or the inhibitory
the basic KRR triplet at positions 305–307 that interferes
with GATA-3 acetylation, but not with DNA binding [24],
and abolishes the ability of GATA-3 to transactivate tar-
get promoters in vitro [23] and in vivo [25]. The KRR
mutation, however, did not interfere with the ability of
GATA-3 to interact with Smad3 as assessed in an in
vitro pull-down assay using GST-Smad3 and in vitro-
translated KRR-GATA-3 (Figure 7C). We generated two
independent clones of HT-2 cells expressing KRR-
GATA-3 (KRR #19 and KRR #20) as well as a clone
expressing wild-type GATA-3 (GATA3 #37). Expression
was confirmed by immunoblotting with antibodies
against an HA tag introduced in all the constructs and
was comparable among the three lines (data not shown).
Subclones and parental HT-2 cells had comparable
Figure 6. TGF- Induces the Formation of an Endogenous Smad3/
growth rates and morphology. In the presence of PMAGATA-3 Complex in the Nucleus of the T Helper Cell Line HT-2
and ionomycin, parental HT-2 cells produced about 6Nuclear extracts of HT-2 cells treated with TGF- (50 min at 10 ng/
ng/ml of IL-10 in the conditioned medium, while theml), as indicated, were immunoprecipitated with anti-GATA-3 (G3)
subclones GATA3 #37 and KRR #19 and #20 made 3or control (ctrl) antibodies and probed with anti-Smad3 antibodies.
Smad3 and IgG bands are indicated. In the experiment shown, the ng/ml and 1 ng/ml, respectively. Treatment with TGF-
cells had also been treated with PMA/ionomycin. Note that Smad3 stimulated IL-10 production in parental HT-2 cells and
coimmunoprecipitates with GATA-3 only in cells treated with TGF-. in cells overexpressing wild-type GATA-3 (Figure 7D).
Smad3 produced in transfected COS cells was run in a parallel lane Cells overexpressing GATA-3 showed a TGF- response
as a size marker. Reprobing of aliquots of the corresponding lysates
comparable to that of parental cells, indicating that(middle and bottom panels) indicates comparable amounts of
GATA-3 is not limiting in HT-2 cells for IL-10 regulationGATA-3 and Smad3. Similar results were obtained in cells that had
not been treated with PMA/ionomycin. by TGF-. In contrast, TGF- had no effect on IL-10
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Figure 7. TGF- Regulation of IL-10 Produc-
tion in HT-2 Cells Is GATA-3 Dependent
(A) IL-10 production in HT-2 supernatants.
HT-2 cells were incubated for 16 hr in serum-
free medium in the presence or absence of
PMA/ionomycin (PI) and TGF- as indicated.
A double asterisk indicates that p  0.01.
(B) IL-10 production in supernatants of unin-
fected HT-2 cells (no virus) or cells infected
with adenoviruses expressing -gal (lacZ),
dominant-negative Smad3 (DN-Smad3), or
Smad7. Following a 2-day infection, cells
were incubated for 16 hr in serum-free me-
dium in the presence of PMA/ionomycin and
TGF- at the concentrations indicated. Re-
sults are denoted relative to IL-10 levels in
uninfected HT-2 cells. A double asterisk indi-
cates that p  0.01.
(C) Interaction of KRR-GATA-3 with Smad3.
35S-labeled KRR-GATA-3 produced by in vitro
translation was used in coprecipitation
assays together with GST-Smad3 or GST
control fusion proteins. As control, 20% of
the 35S-labeled KRR-GATA-3 used for the pre-
cipitations was included (20% input).
(D) IL-10 production in supernatants of paren-
tal HT-2 cells and subclones overexpressing
wild-type GATA-3 (GATA3 #37) or a domi-
nant-negative GATA-3 (KRR #19 and KRR
#20). Cells were incubated for 16 hr in serum-
free medium in the presence of PMA/iono-
mycin and TGF- at the concentrations indi-
cated. Results are indicated relative to IL-10
levels in the absence of TGF- produced by
each cell line. A double asterisk indicates that
p  0.01.
production in the two subclones overexpressing the are still uncharacterized. The many factors currently
dominant-negative KRR-GATA-3 (Figure 7D). These re- known to interact with Smads are simply not sufficient
sults indicate that endogenous GATA-3 function is nec- to explain the tissue-specific biology of TGF- proteins.
essary for TGF- to regulate the production of IL-10 in In the present work, we show that GATA-3, a master
HT-2 cells. regulator of cell fate and differentiation in the immune
and nervous systems, is a tissue-restricted partner of
Smad proteins. We found that TGF- induces a specificDiscussion
interaction between Smad3 and GATA-3 in T cells,
thereby recruiting Smad3 to GATA DNA binding sitesDespite recent significant advances in the identification
and allowing TGF- regulation of GATA-3 target pro-of general transcription factors that collaborate with
moters.Smad proteins to regulate TGF--dependent gene tran-
Ligand binding to TGF- receptors causes activationscription, a complete understanding of the mechanisms
and nuclear translocation of Smad proteins. Receptor-by which TGF-proteins contribute to the establishment
specific Smads, such as Smad3, form heteromeric com-of distinct cell phenotypes will not be attained until the
plexes with Smad4 to activate or repress genes in col-tissue-restricted factors that cooperate with Smads to
laboration with cofactors. We found that Smad4 did notcontrol cell type-specific gene expression are identified.
form part of the Smad3/GATA-3 nuclear complexes, norIn the immune and nervous systems, in which TGF-
did it affect the functional interaction of Smad3 andproteins play key roles in patterning and cell differentia-
tion, the specific factors responsible for these effects GATA-3 on the IL-5 promoter, suggesting that Smad4
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does not play a direct role in the regulation of GATA-3 between Smad3 and GATA-3 may allow us to rationalize
some of the activities of TGF- proteins in immune cells.target genes by TGF-. Smad3 can bind DNA with low
affinity, and recent studies have found a variable require- As shown here and in other studies [41, 42], TGF- can
acutely upregulate cytokine production by effector cells,ment of DNA binding for transactivation by this protein.
Collaboration of Smad3 with c-Jun and transactivation an effect likely to be mediated through the cooperation
of Smad proteins with key transcription factors such asof gene expression from AP-1 sites in the collagenase
I gene promoter appears to require binding of Smad3 GATA-3. On the other hand, feedback regulatory loops
activated by TGF- signaling result in longer-term inhibi-to DNA, although not in a DNA sequence-specific man-
ner [26]. On the other hand, Smad3 can be recruited tory effects on immune cell function. It has been shown,
for example, that a 5-day treatment with TGF- inhibitsby the general transcription factor Sp1 to activate the
p21Waf1/Cip1 gene promoter independently of Smad3 bind- Th2 helper cell differentiation and cytokine production,
interestingly enough, by preventing upregulation ofing to DNA [27]. Similar to this latter case, we also found
that GATA-3 can recruit Smad3 to a GATA-specific DNA GATA-3 expression during activation of naı¨ve T helper
cell precursors [39, 40]. This could represent an inhibi-binding site, and that a Smad3 mutant deficient in DNA
binding can still cooperate with GATA-3 to transactivate tory feedback mechanism to limit the cooperation be-
tween GATA-3 and TGF- signaling. Cellular context isthe IL-5 promoter in a TGF--dependent manner.
Both MH1 and MH2 domains in Smad proteins have also an important determinant of the activity of Smad
proteins, as these are capable of interacting with bothbeen implicated in protein-protein interactions with dif-
ferent cofactors [11], while, in Smad3, only the MH1 coactivators, such as p300/CBP [43–45], and corepres-
sors, such as TGIF, c-Ski, and SnoN [46–48]. For exam-domain has the ability to interact with DNA [17, 18]. We
found that Smad3 interacts with GATA-3 through its ple, a recent study showed that the interaction between
Smad3 and the osteoblast transcription factor CBFA1MH1 domain. This domain has been shown to mediate
association of Smad3 with a number of general tran- resulted in repression of the OSE2 promoter in mesen-
chymal cells, but in activation of the same promoter inscription factors, including c-Jun [28], ATF-2 [29], TFE3
[30], and Sp1 [27]. Cofactor interaction with MH1 versus epithelial cells [49]. In this regard, it should be noted that
one study found that TGF- inhibited IL-5 production byMH2 domains does not appear to correlate with the
requirement of Smad3 to bind DNA, as several examples polyclonally activated human T cells [50]. Although we
observed a synergistic cooperation between Smad3 andhave been found of protein-protein interactions involv-
ing the Smad3 MH1 domain that require [26, 30] or do GATA-3 in the activation of the IL-5 promoter in both
epithelial and lymphoid cells, the construct that we usednot require [27] binding of this Smad to DNA. In the case
of GATA-3, the Smad interaction domain appears to contained only 1.2 kb of upstream sequence, so we
cannot rule out that Smad3 exerts a different effect onreside in the central portion of the molecule upstream
of the two C-terminal zinc finger domains, which are the the endogenous, full-length IL-5 promoter and that this
may also be cell context dependent. Thus, although theones believed to mediate GATA-3 binding to DNA.
TGF- family proteins have multiple and often per- Smad3/GATA-3 interaction can confer TGF- respon-
siveness to specific target promoters, the functional out-plexing effects on immune cell function, displaying both
inhibitory and stimulatory activities. Many of the inhibi- come of this interaction, i.e., activation or repression, will
likely depend on the presence or absence of additionaltory effects of TGF-s are due to their powerful antipro-
liferative activity, mediated in part through the induction cofactors, themselves subject to cell type-specific and
temporal regulation.of cell cycle inhibitors [27, 31–33]. TGF- has also been
shown to downregulate immune cell function indepen- In the T helper cell line HT-2, we found that TGF-
regulates IL-10 production in a Smad3- and GATA-3-dently of its antiproliferative effects through the regula-
tion of specific genes required for lymphocyte differ- dependent manner. Both TGF- and IL-10 are often as-
sociated with downregulation of Th1-like immune re-entiation and function [12, 13]. On the other hand,
stimulatory activities of TGF- in immune cells include sponses and a shift toward Th2-like responses [35, 37].
TGF- has been reported to increase IL-10 productionthe induction of extracellular matrix proteins, regulation
of cytokine production, and antiapoptotic effects [12, in macrophages [41], and both cytokines contribute to
the suppression of macrophage functions [35]. TGF-13]. In addition, TGF- proteins are known to elicit differ-
ent effects at different concentrations. Thus, for exam- and IL-10 have also been implicated in the induction of
immune privilege in the anterior chamber of the eye asple, TGF- has been shown to stimulate IL-2 production
at very low concentrations (0.1–1 pg/ml) and to con- a result of downregulation of Th1 immune responses
[42]. Thus, TGF- contributes to the production of aversely inhibit IL-2 production at higher concentrations
(1–10 ng/ml) in the same cell type [34], which is reminis- cytokine, IL-10, that has a similar functional profile in
immune cells, namely, suppression of monocyte andcent of our own results on IL-10 production by HT-2
cells. TGF- also has stimulatory [35–37] and inhibitory Th1 immune responses.
Our results also have implications for other systems[38–40] effects on the differentiation and function of Th2
helper cells depending on the cellular context and the in which GATA-3 and TGF- signaling converge to con-
trol cell-specific differentiation events. For example,presence or absence of costimulatory signals. A big
obstacle for the understanding of the paradoxical ef- GATA-3 has been shown to be required for the specifica-
tion of the neurotransmitter phenotype of sympatheticfects of TGF- in immune cell differentiation and func-
tion has been the lack of specific molecular targets of neurons [5]. Loss of GATA-3 leads to deficits in tyrosine
hydroxylase (TH) and dopamine -hydroxylase (DBH)the TGF--signaling pathway in immune cells.
Our finding of a physical and functional interaction expression, which results in reduced noradrenaline in
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Cell Transfection, Adenovirus Infection, Reporter Assays,the sympathetic nervous system and embryonic lethality
and IL-10 ELISA[5]. TGF- proteins, in particular BMP-2, BMP-4, and
COS cells were transfected by the calcium phosphate method.BMP-7, direct noradrenergic differentiation of sympa-
HepG2 and Jurkat cells were transfected in complete medium with
thetic neurons by inducing TH and DBH expression in FuGene6 according to the manufacturer’s instructions (Roche). After
collaboration with other transcription factors [51, 52]. a 24-hr incubation, cell monolayers were washed with serum-free
medium and incubated for an additional 16 hr in 0.1% serum-con-Based on our present results, we hypothesize that
taining medium supplemented with TGF-1 (R&D, 10 ng/ml, unlessGATA-3 may collaborate with Smad proteins to stimu-
otherwise indicated) and PMA/ionomycin (50 ng/ml and 750 ng/ml,late noradrenergic differentiation in sympathetic neuron
respectively) as indicated. Reporter assays were analyzed using theprecursors. In another recent example, adipocyte differ-
Dual-Luciferase Reporter Assay System kit from Promega. Firefly
entiation was shown to be regulated by GATA-3 through luciferase activity was normalized to the Renilla luciferase activity,
molecular control of the preadipocyte-adipocyte transi- and fold induction was calculated relative to the luciferase activity
in control conditions. Luciferase expression was quantified on ation [53]. GATA-3 overexpression suppressed adipocyte
1450 Microbeta Jet luminescence counter (Wallac). All treatmentsdifferentiation, while GATA-3 loss resulted in an en-
and transfection conditions were analyzed in triplicate.hanced capacity to differentiate into adipocytes [53].
The treatment with PMA/ionomycin activates cAMP and Ca2Interestingly, TGF- is a well-known negative regulator pathways and mimics antigen stimulation of immune cells. Two
of adipocyte differentiation [54, 55]. As with the GATA-3 assays utilized in the present study, namely, induction of the IL-5-
experiments, interference with TGF- receptor signaling Luc reporter construct and production of IL-10, require this treat-
ment. Reporter assays based on multimerized GATA or CAGA sites,enhanced adipocyte differentiation, while overexpres-
as well as the biochemical assays, do not require this treatment,sion of Smad3 inhibited differentiation [55]. Thus, collab-
and, in most cases, these were performed in the absence of PMA/oration of these two pathways through the direct interac-
ionomycin (exceptions are indicated in the figure legends). We
tion of GATA-3 with Smad3 may also play a role, in this found, however, that none of the biochemical assays were influ-
case inhibitory, in the regulation of adipocyte differenti- enced by treatment with these drugs. The coimmunoprecipitation
ation. assay demonstrating interaction between endogenous Smad3 and
GATA-3 in HT-2 cells shown in Figure 6 was performed in the pres-
ence of PMA/ionomycin, i.e., in the same cellular environment that
Conclusions allowed induction of IL-10 production by TGF-. Of note, this inter-
action could also be observed in the absence of drug treatment.We present evidence that GATA-3, a tissue-restricted
HT-2 cells were transfected by electroporation. Stable popula-factor and “master” regulator of T helper cell develop-
tions of transfected cells were selected in G418 (Life Technologies).ment, can also integrate information from extracellular
After amplification, clones of cells were obtained by limiting dilution
TGF- signals by physically and functionally interacting and were analyzed for gene expression by Western blotting with
with the signal-activated factor Smad3. The interaction anti-HA antibodies. Adenoviruses were kindly provided by Aristidis
Moustakas, LICR, Uppsala, Sweden. HT-2 cells were infected inbetween GATA-3 and Smad3 may allow TGF- signaling
medium containing 3% serum at 100:1 multiplicity of infection forto access the promoters of specific sets of genes in-
48 hr prior to TGF- stimulation. Infection was estimated to bevolved in cell fate and differentiation in the immune and
greater than 70% by -gal staining of cells infected with lacZ viruses.
nervous systems. These results provide a molecular The IL-10 ELISA was performed using a kit from R&D. Cells were
framework for the effects of TGF- on the development preincubated for 4–6 hr in IL-2/ME-supplemented serum-free me-
and function of specific subsets of immune cells and dium, and were then plated in 96-well plates (2  105 cells in 200
	l) in HT-2 serum-free medium supplemented with PMA/ionomycinpossibly other cell types.
and TGF-1 (R&D) as indicated. Conditioned media were harvested
after an overnight incubation, and 50 	l was assayed following the
Experimental Procedures manufacturer’s instructions. All conditions were analyzed in quadru-
plicate.
Cell Lines and Plasmid Constructs
COS cells were grown in DMEM, HepG2 cells were grown in MEM, Electrophoretic Mobility Shift Assays
and Jurkat and HT-2 cells were grown in RPMI, all supplemented Nuclear extracts were prepared from control and TGF--treated (50
with 10% fetal bovine serum and antibiotics. HT-2 cells also received min) HT-2 cells using high-salt extraction. Briefly, 2  108 cells from
fresh IL-2 and -mercaptoethanol every 2 days. The IL-5 reporter suspension cultures were collected by centrifugation and washed
construct contains 1.2 kb of upstream sequence of the IL-5 gene with phosphate buffer saline (PBS). The pellet was resuspended in
(GenBank accession number D14461.1) followed by a luciferase 1 ml ice-cold homogenization buffer (25 mM Tris-HCl [pH 7.5], 0.32 M
reporter [16, 56] and was kindly provided by Naoko Arai. Mutagene- Sucrose, 30 mM NaF, 1 mM Na3VO4, 1Complete protease inhibitor
sis of the GATA-3 binding site in this promoter construct was per- cocktail [Roche]) and was allowed to swell on ice for 20 min followed
formed by replacing the 5-TATCTGA-3 heptamer in the conserved by 20 strokes of a Dounce all-glass homogenizer. The nuclei were
lymphokine element 2 (CLE2) motif [16, 56] with 5-GCGACTC-3 collected by centrifugation, washed, and lysed in a high-salt buffer
using the QuickChange Mutagenesis System from Stratagene. A containing 420 mM NaCl, 10% glycerol, 20 mM Tris-HCl (pH 7.9), 1
synthetic GATA reporter construct was generated by introducing mM DTT, 30 mM NaF, 1 mM Na3VO4, and 1 Complete protease
three tandem copies in the forward direction of an oligonucleotide inhibitor. After 30 strokes in a Dounce all-glass homogenizer, the
containing two consensus binding sites for GATA factors (5-CACT nuclei fractions were incubated under agitation on ice for 40 min,
TGATAACAGAAAGTGATAACTCT-3) upstream of the adenovirus then collected by centrifugation at 14,000  g for 30 min, and the
major late promoter in the pGL3 plasmid from Promega. The CAGA supernatant was aliquotted and stored at 80
C.
reporter contains nine tandem copies of the SBE from the plasmino- A total of 5 	g of nuclear extracts from HT-2 or COS cells were
gen activator inhibitor-1 (PAI-1) promoter and was described pre- incubated in 20 	l binding buffer (10 mM Tris-HCl [pH 7.5], 50 mM
viously [17]. All Smad expression plasmids used the pCDNA3 back- NaCl, 1 mM MgCl2, 4% glycerol, 0.5 mM DTT, 1 	g Poly [dI-dC]).
bone and have been described elsewhere [20]. GATA-3 expression After 30 min (45 min with antibody for supershift) on ice, complexes
plasmids were based in the pCDNA3 backbone. The mutant KRR- were separated on a 6% polyacrylamide gel and run in 0.5 TBE.
GATA-3 was kindly provided by A. Winoto. The constitutively acti- Oligonucleotides containing two consensus binding sites for GATA
vated TGF- receptor (CA-ALK5) carries a mutation in the intracellu- factors were used: 5-CACTTGATAACAGAAAGTGATAACTCT-3
lar juxtamembrane domain (T204D) and has been described pre- and its complementary strand. Oligonucleotides were end labeled
with -32P-ATP using polynucleotide kinase (PNK).viously [57, 58].
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GST Pull Downs, Immunoprecipitations, 10. Massague´, J., and Chen, Y.-G. (2000). Controlling TGF- signal-
ing. Genes Dev. 14, 627–644.and Western Blotting
GST fusions were produced in E. coli and purified by chromatogra- 11. ten Dijke, P., Miyazono, K., and Heldin, C.-H. (2000). Signaling
inputs converge on nuclear effecters in TGF-beta signaling.phy on glutathione-conjugated agarose beads (Pharmacia). In vitro-
translated products were produced using a kit from Promega. Anti- TIBS 25, 64–70.
12. Cerwenka, A., and Swain, S.L. (1999). TGF-1: immunosuppres-body against GATA-3 was from Santa Cruz, anti-HA monoclonal
was from Covance, anti-myc monoclonal antibody was obtained sant and viability factor for T lymphocytes. Microbes Infect. 1,
1291–1296.from the conditioned medium of the 9E1 hybridoma, and anti-Smad3
antibodies were previously described [59]. Nuclear extracts were 13. Letterio, J.J., and Roberts, A.B. (1998). Regulation of immune
responses by TGF-. Annu. Rev. Immunol. 16, 137–161.obtained by high-salt extraction of nuclear pellets. Immunoprecipi-
tations were done overnight at 4
C, followed by incubation with 14. Yang, X., Letterio, J.J., Lechleider, R.J., Chen, L., Hayman, R.,
Gu, H., Roberts, A.B., and Deng, C. (1999). Targeted disruptionProteinG Gamma-Bind beads (Pharmacia), repeated washing steps,
and elution in SDS/PAGE sample buffer. Immunoprecipitates were of SMAD3 results in impaired mucosal immunity and diminished
T cell responsiveness to TGF-. EMBO J. 18, 1280–1291.fractionated by SDS-PAGE and blotted to PVDF membranes (Amer-
15. Datto, M.B., Frederick, J.P., Pan, L., Borton, A.J., Zhuang, Y.,sham). Blots were probed with the indicated antibodies, followed
and Wang, X.F. (1999). Targeted disruption of Smad3 reveals anby alkaline phosphatase-conjugated anti-IgG and were developed
essential role in transforming growth factor--mediated signalwith the ECF Western Detection System (Amersham). Gels with in
transduction. Mol. Cell. Biol. 19, 2495–2504.vitro-translated products were fixed, dried, and exposed to phos-
16. Lee, H.J., O’Garra, A., Arai, K., and Arai, N. (1998). Characteriza-phorscreens. All blots and gels were scanned in a Storm 840 phos-
tion of cis-regulatory elements and nuclear factors conferringphorimager/fluorimager and quantified with ImageQuant software
Th2-specific expression of the IL-5 gene: a role for a GATA-(Molecular Dynamics).
binding protein. J. Immunol. 160, 2343–2352.
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